Repligen (RGEN)
(Delayed Data from NSDQ)
$146.95 USD
+4.81 (3.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $146.98 +0.03 (0.02%) 5:30 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.95 USD
+4.81 (3.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $146.98 +0.03 (0.02%) 5:30 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Repligen (RGEN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Repligen (RGEN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Repligen (RGEN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 50.00% and 11.98%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks
by Aniruddha Ganguly
Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.
Repligen (RGEN) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QGEN vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
by Zacks Equity Research
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
Profit From 5 Stocks Likely to Beat on Earnings
by Sanghamitra Saha
Bet on five stocks that are likely to outdo earnings estimates.
Why Repligen (RGEN) Might be Well Poised for a Surge
by Zacks Equity Research
Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 45.46% and 5.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
Should Growth Investors Buy this Cancer Screening Biotech Stock?
by Benjamin Rains
Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?
Intercept (ICPT) Concludes Enrollment in Study on NASH Drug
by Zacks Equity Research
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
by Zacks Equity Research
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
3 Reasons Growth Investors Will Love Repligen (RGEN)
by Zacks Equity Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.